Discovery of 4-substituted-8-(2-hydroxy-2-phenyl-cyclohexyl)-2,8-diaza-spiro[4.5]decan-1-one as a novel class of highly selective GlyT1 inhibitors with improved metabolic stability

This publication has 11 references indexed in Scilit:

• Discovery of N-(2-aryl-cyclohexyl) substituted spiropiperidines as a novel class of GlyT1 inhibitors
  Bioorganic & Medicinal Chemistry Letters, 2006
• Discovery of N-(2-hydroxy-2-aryl-cyclohexyl) substituted spiropiperidines as GlyT1 antagonists with improved pharmacological profile
  Bioorganic & Medicinal Chemistry Letters, 2006
• Glycine Transporter Inhibitors as Therapeutic Agents for Schizophrenia
  Recent Patents on CNS Drug Discovery, 2006
• Glycine transporters: essential regulators of neurotransmission
  Trends in Biochemical Sciences, 2005
• N-Methyl-d-aspartate receptors as a target for improved antipsychotic agents: novel insights and clinical perspectives
  Psychopharmacology, 2005
• The therapeutic potential of glycine transporter-1 inhibitors
  Expert Opinion on Investigational Drugs, 2004
• Glycine transporter I inhibitor, N-Methylglycine (sarcosine), added to antipsychotics for the treatment of schizophrenia
  Published by Elsevier ,2004
• Recent progress in the use of glycine transporter-1 inhibitors for the treatment of central and peripheral nervous system diseases
  Expert Opinion on Therapeutic Patents, 2004
• Synthesis of (1S,3aS)-8-(2,3,3a,4,5,6-hexahydro-1H-phenalen-1-yl)-1-phenyl-1,3,8-triaza-spiro[4.5]decan-4-one, a potent and selective orphanin FQ (OFQ) receptor agonist with anxiolytic-like properties
  European Journal of Medicinal Chemistry, 2000
• Modulation of N -methyl- d -aspartate receptor function by glycine transport
  Proceedings of the National Academy of Sciences, 1998